Decoding biology to radically improve lives
Recursion was founded more than a decade ago on the idea that we could take images of cells and use these images to train artificial intelligence to understand the vast unknown biological space – the cellular disruptions driving disease – to use AI-drug discovery to reduce the massive 90% failure rate of traditional drug discovery.
Our missionBetter medicines, through novel insights and precision design
We’re using data and AI to bring better medicines to patients, faster.
The Recursion OS drug discovery and development platform has yielded an advanced pipeline of potential first-in-class and best-in-class treatments for conditions with high unmet need including aggressive cancers and rare diseases. Today, we’ve demonstrated significant improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical company averages.
Inside the loop: Learn how we map disease biology and design potential medicines, and carry them into the clinic — at scale
Take a look inside the automated labs that form our AI-native data factory to see our end-to-end drug discovery and development engine work as one connected system. Driven by bilingual teams of scientists and technologists, our wet and dry "lab-in-the-loop," forms a continuous learning system of physical automation and machine learning models. See how we run up to 2 million weekly experiments to build a 50+ petabyte proprietary dataset, tightly connecting biology, generative de novo chemistry, and translational clinical tools to systematically de-risk drug discovery.
Explore our technologyDelivering for our partners
Our strategic partnerships allow us to accelerate the discovery of new medicines and expand our potential impact on patients via AI-drug discovery.
This includes pharmaceutical partnerships with industry leaders, technology partnerships with computational titans, and next-generation data partnerships that enhance our capabilities and generative AI for pharma as one of the top AI drug discovery companies in the industry.
The latest from Recursion
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
Read more →Leveraging the Power of Patient Data in AI-Drug Discovery
Read more →Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market
Read more →
